Serogroup Men+Tdap+HPV Placebo+Tdap+HPV
  n GMT / % of subjects n GMT / % of subjects
A 371   99  
GMTs        
 Baseline   2.2 (2.1, 2.3)   2.1 (2.0, 2.3)
1 month post-vaccination   35 (29, 42)   2.1(2.0, 2.3)
hSBAtiter ≥8, %   77 (72, 81)   2 (0, 7)
Seroresponders, %   75 (70, 80)   1 (0, 5)
C 370   97  
 GMTs        
 Baseline   4.4 (4.0, 4.9)   3.9 (3.3, 4.6)
 1 month post-vaccination   59 (48, 73)   3.9 (3.3, 4.7)
hSBA titer ≥8, %   84 (80, 88)   21 (13, 30)
Seroresponders, %   69 (64, 74)   2 (0, 7)
W-135 369   96  
GMTs        
 Baseline   12 (10, 14)   12 (9.1, 16)
 1 month post-vaccination   61 (53, 69)   12 (9.3, 17)
hSBAtiter ≥8, %   95 (93, 97)   67 (56, 76)
Seroresponders, %   49 (44, 54)   5 (2, 12)
Y 369   97  
GMT        
Baseline   4.1 (3.7, 4.6)   3.5 (2.8, 4.3)
 1 month post-vaccination   48 (40, 58)   3.5 (2.9, 4.3)
hSBAtiter ≥8, %   86 (82, 89)   22 (14, 31)
Seroresponders, %   69 (64, 74)   3 (1, 9)
Table 3: Immunogenicity endpoints for meningococcal serogroups A, C, W-135 and Y responses. hSBA GMTs, percentage of subjects with hSBA titer ≥8, and percentage of seroresponders against serogroups A, C, W-135, and Y, at baseline (GMTs only) and one month post vaccination, by group.